U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
191431191431Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNo Results AvailableChronic Myelogenous LeukemiaDrug: decitabine (5-aza-2'deoxycytidine)https://ClinicalTrials.gov/show/NCT00041990
191432191432Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne RosaceaCompletedNo Results AvailableAcne RosaceaDrug: doxycycline hyclate 20 mg twice dailyhttps://ClinicalTrials.gov/show/NCT00041977
191433191433A Study of HIV Levels During Pregnancy and After ChildbirthCompletedNo Results AvailableHIV Infections|Pregnancyhttps://ClinicalTrials.gov/show/NCT00041964
191434191434Search for Genes Influencing Childhood Absence Epilepsy (CAE) StudyRecruitingNo Results AvailableChildhood Absence Epilepsy|Epilepsy|Seizureshttps://ClinicalTrials.gov/show/NCT00041951
191435191435Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) TrialCompletedHas ResultsHeart Disease|Stroke|Ischemic Heart Disease|Myocardial InfarctionDrug: aspirin|Drug: Warfarinhttps://ClinicalTrials.gov/show/NCT00041938
191436191436Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass ProceduresCompletedNo Results AvailablePeripheral Vascular Diseases|Arterial Occlusive Diseases|Ischemia|Graft Occlusion, Vascular|HyperplasiaDrug: CGT003 (E2F Duplex Decoy)https://ClinicalTrials.gov/show/NCT00041925
191437191437Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914CompletedNo Results AvailableHealthyDrug: CDB-2914|Drug: COB-2914https://ClinicalTrials.gov/show/NCT00041899
191438191438Radiofrequency Ablation of Painful Soft Tissue NeoplasmsCompletedNo Results AvailableSoft Tissue Neoplasmshttps://ClinicalTrials.gov/show/NCT00041886
191439191439Modulation of Benzene Metabolism by Exposure to EnvironmentCompletedNo Results AvailableLung Diseases|CancerProcedure: Controlled Exposure to Environmental Contaminanthttps://ClinicalTrials.gov/show/NCT00041860
191440191440Gene-Environment Interaction in Prostate CancerCompletedNo Results AvailableProstate Cancerhttps://ClinicalTrials.gov/show/NCT00041847
191441191441Geographic Modeling of Traffic and Asthma RatesCompletedNo Results AvailableAsthmahttps://ClinicalTrials.gov/show/NCT00041834
191442191442Nasal Irritation Study: Individual Factors in Nasal Irritant SensitivityCompletedNo Results AvailableRhinitis, Allergic, NonseasonalProcedure: Nasal irritation thresholds and irritant provocationhttps://ClinicalTrials.gov/show/NCT00041821
191443191443Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the LiverCompletedNo Results AvailableMetastases, Neoplasm|Colorectal Neoplasms|Esophageal Neoplasms|Stomach Neoplasms|Pancreatic Neoplasms|Breast Neoplasms|Melanoma|Sarcoma|Gastrointestinal Neoplasms|Lung Neoplasms|Liver Neoplasms|CholangiocarcinomaDrug: MTC-DOX for Injection|Procedure: Chemotherapyhttps://ClinicalTrials.gov/show/NCT00041808
191444191444Neotrofin for Treatment of Chemotherapy-Induced Peripheral NeuropathyCompletedNo Results AvailablePeripheral Nervous System Diseases|Chemotherapy-Induced Peripheral NeuropathyDrug: leteprinim potassium (Neotrofin)https://ClinicalTrials.gov/show/NCT00041795
191445191445Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer PatientsTerminatedNo Results AvailableNeoplasms|Deep Vein ThrombosisDrug: Dalteparin (Fragmin)https://ClinicalTrials.gov/show/NCT00041782
191446191446Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease InhibitorCompletedNo Results AvailableHIV InfectionsProcedure: Therapeutic Drug Monitoring (TDM)https://ClinicalTrials.gov/show/NCT00041769
191447191447Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee OsteoarthritisCompletedHas ResultsOsteoarthritis, KneeDrug: PG-530742|Drug: Placebo|Drug: 50 mg PG-530742|Drug: 100 mg PG-530742|Drug: 200 mg PG-530742https://ClinicalTrials.gov/show/NCT00041756
191448191448Treatment of Binge Eating DisorderCompletedNo Results AvailableBinge Eating DisorderBehavioral: Group Cognitive Behavioral Therapyhttps://ClinicalTrials.gov/show/NCT00041743
191449191449Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's LymphomaActive, not recruitingNo Results AvailableNon-Hodgkin's LymphomaBiological: Id-KLHhttps://ClinicalTrials.gov/show/NCT00041730
191450191450Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedHas ResultsSpinal Cord Injury|Muscle SpasticityDrug: Fampridine-SR|Other: Placebohttps://ClinicalTrials.gov/show/NCT00041717
191451191451The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)CompletedNo Results AvailableCandidiasisDrug: Anidulafungin, VER002https://ClinicalTrials.gov/show/NCT00041704
191452191452Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After SurgeryTerminatedNo Results AvailableColorectal NeoplasmsDrug: hMN14 (labetuzumab)https://ClinicalTrials.gov/show/NCT00041691
191453191453Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCompletedNo Results AvailableAlzheimer DiseaseDrug: aripiprazolehttps://ClinicalTrials.gov/show/NCT00041678
191454191454Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose ChemotherapyCompletedNo Results AvailableStomatitisDrug: Recombinant Human Keratinocyte Growth Factorhttps://ClinicalTrials.gov/show/NCT00041665
191455191455Safety Study of hMN14 to Treat Either Colorectal or Breast CancerCompletedNo Results AvailableColorectal Cancer|Colon Cancer|Rectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Breast Cancer|Breast NeoplasmsDrug: hMN14 (labetuzumab)https://ClinicalTrials.gov/show/NCT00041652
191456191456Safety Study of 90Y-hMN14 to Treat Pancreatic CancerCompletedNo Results AvailablePancreatic NeoplasmsDrug: hMN14 (labetuzumab)https://ClinicalTrials.gov/show/NCT00041639
191457191457Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneRecruitingNo Results AvailableCarcinoma, Squamous CellGenetic: INGN 201https://ClinicalTrials.gov/show/NCT00041626
191458191458Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateRecruitingNo Results AvailableCarcinoma, Squamous CellGenetic: INGN 201https://ClinicalTrials.gov/show/NCT00041613
191459191459Human Epilepsy Genetics--Neuronal Migration Disorders StudyRecruitingNo Results AvailableEpilepsy|Seizures|Cognition Disorders|Neuronal Migration Disordershttps://ClinicalTrials.gov/show/NCT00041600
191460191460Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant GliomaCompletedNo Results AvailableMalignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Mixed OligoastrocytomaDrug: IL13-PE38QQR|Procedure: targeted fusion protein therapy|Procedure: surgeryhttps://ClinicalTrials.gov/show/NCT00041587

* Görseller ve İçerik tekif hakkına sahip olabilir